June 7, 2021: A Historic Day

On June 7, 2021, the FDA approved Biogen drug aducanumab, the first-ever disease-modifying therapy for early stage Alzheimer's disease. Through the years, we have never let go of hope, but this feels like a true turning point. As pointed out in the UsAgainstAlzheimer's (UsA2) press release below, with the approval of this first drug, the second, third, fourth, and beyond, should follow at a more rapid pace.

Continue reading →